CD International Enterprises (CDII) Sourcing Commo
Post# of 171
(Total Views: 872)
Posted On: 07/17/2017 5:27:59 PM
CD International Enterprises (CDII) Sourcing Commodities and CBD
- Proven track record sourcing/delivering commodities to Chinese clients
- Extensive experience and relationships in Chinese practices and protocols
- One of the first to distribute CBD to Chinese speaking people
CD International Enterprises, Inc. (OTC: CDII), which sources and distributes industrial commodities for Chinese clients, is on a tear. The company continues to rack up purchase contracts and corporate offers for invaluable commodities slated for delivery to China’s industrial sector. CDII just announced that it has entered into another purchase contract to acquire 10,000 metric tons of copper concentrate per month over a 12-month period from a Chile-based company. CDII’s initial 12-month contract total of 120,000 metric tons of copper concentrate is valued at about $260 million based on current copper future prices. This contract comes on the heels of a full corporate offer announced in late May for the monthly purchase of 100,000 tons of metallurgic-grade bauxite, with the initial 12-month contract valued near $37 million.
May was a busy month for the global commodity player. On May 10, the company announced a full corporate offer to purchase 5,000 tons of copper cathodes per month from a Tanzania-based company. The total shipment of 60,000 metric tons of copper cathodes over 12 months is valued at approximately $330 million. Earlier in May, CD International announced a letter of intent to purchase 100,000 metric tons of iron ore per month over 12 months. The initial 12-month contract of 1.2 million metric tons of iron ore is valued around $84 million, and CDII has the option to increase supply to 500,000 metric tons per month, or six million metric tons of iron ore per year.
With over $700 million in sourced orders in just the last three months, CDII’s years of building global relationships and honing logistical experience are showing significant results, but the best may be yet to come. Not only is the company committed to dramatically expanding its commodities business, it has also targeted a new arena of explosive growth. Leveraging its years of experience and relationships, CDII has expanded into one of the fastest growing markets in the world, medical marijuana.
CD International has become one of the very first to companies distribute and sell medicinal cannabidiol (CBD) based products to the 2+ billion Chinese-speaking people. The company recently formed its Green Products division and online retail store (http://www.greencbdproducts.com/cbd) to facilitate its bold initiative and capture a large share of the projected 17 percent compounded annual growth rate. Non-euphoric CBD-based products are legal in China, blend with Chinese holistic medicine and have a broad range of clinically-proven therapeutic uses, including treating epilepsy, anxiety, pain and nausea.
Because the natural extract of CBD-based products is so similar to traditional Chinese medicine, management believes there is a huge opportunity in Chinese-speaking communities for CBD-based products. Given CDII’s track record in global commodity sourcing, its long standing relationships within China and its deep understanding of Chinese culture and practices, CD International’s latest undertaking has blockbuster potential.
For more information, visit the company’s website at www.CDII.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
- Proven track record sourcing/delivering commodities to Chinese clients
- Extensive experience and relationships in Chinese practices and protocols
- One of the first to distribute CBD to Chinese speaking people
CD International Enterprises, Inc. (OTC: CDII), which sources and distributes industrial commodities for Chinese clients, is on a tear. The company continues to rack up purchase contracts and corporate offers for invaluable commodities slated for delivery to China’s industrial sector. CDII just announced that it has entered into another purchase contract to acquire 10,000 metric tons of copper concentrate per month over a 12-month period from a Chile-based company. CDII’s initial 12-month contract total of 120,000 metric tons of copper concentrate is valued at about $260 million based on current copper future prices. This contract comes on the heels of a full corporate offer announced in late May for the monthly purchase of 100,000 tons of metallurgic-grade bauxite, with the initial 12-month contract valued near $37 million.
May was a busy month for the global commodity player. On May 10, the company announced a full corporate offer to purchase 5,000 tons of copper cathodes per month from a Tanzania-based company. The total shipment of 60,000 metric tons of copper cathodes over 12 months is valued at approximately $330 million. Earlier in May, CD International announced a letter of intent to purchase 100,000 metric tons of iron ore per month over 12 months. The initial 12-month contract of 1.2 million metric tons of iron ore is valued around $84 million, and CDII has the option to increase supply to 500,000 metric tons per month, or six million metric tons of iron ore per year.
With over $700 million in sourced orders in just the last three months, CDII’s years of building global relationships and honing logistical experience are showing significant results, but the best may be yet to come. Not only is the company committed to dramatically expanding its commodities business, it has also targeted a new arena of explosive growth. Leveraging its years of experience and relationships, CDII has expanded into one of the fastest growing markets in the world, medical marijuana.
CD International has become one of the very first to companies distribute and sell medicinal cannabidiol (CBD) based products to the 2+ billion Chinese-speaking people. The company recently formed its Green Products division and online retail store (http://www.greencbdproducts.com/cbd) to facilitate its bold initiative and capture a large share of the projected 17 percent compounded annual growth rate. Non-euphoric CBD-based products are legal in China, blend with Chinese holistic medicine and have a broad range of clinically-proven therapeutic uses, including treating epilepsy, anxiety, pain and nausea.
Because the natural extract of CBD-based products is so similar to traditional Chinese medicine, management believes there is a huge opportunity in Chinese-speaking communities for CBD-based products. Given CDII’s track record in global commodity sourcing, its long standing relationships within China and its deep understanding of Chinese culture and practices, CD International’s latest undertaking has blockbuster potential.
For more information, visit the company’s website at www.CDII.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)